Plain-English translation of NCT04766866 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a straightforward approach to prevent preeclampsia—a serious pregnancy complication involving high blood pressure—in women carrying their first baby. Researchers will use a blood test that measures two proteins (called sFlt1 and PlGF) at 35-36 weeks of pregnancy to identify women at highest risk. If your blood test shows high risk, you'll be offered the option to have your labor induced at 37 weeks, which may prevent preeclampsia from developing.
Preeclampsia is a dangerous condition that can harm both mother and baby, especially near the end of pregnancy. Currently, doctors don't have a simple, practical way to predict who will develop it close to term, and no proven treatment to prevent it. This trial is testing whether catching high-risk cases early with a single blood test and offering early delivery could reduce how many women develop this serious complication.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll have a blood test at 35-36 weeks of pregnancy to measure the two proteins related to preeclampsia risk. Half of participants will learn their results right away; the other half won't be told until after delivery (this helps researchers see if knowing the results makes a real difference). If you're in the group that learns your results and they're high-risk, you can choose to have your labor induced at 37 weeks. Either way, you'll continue with routine pregnancy care and delivery.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
Belgium
Colombia
Czechia
Ecuador
India